Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Schroders Capital Global Innovation Trust PLC - London-based investment trust focused on a portfolio of ‘highly innovative’ companies - Notes second follow-on investment in iOnctura BV, a clinical-stage biotech firm that focuses on combating neglected and hard-to-treat cancers by developing experimental oral small molecule treatments designed to maximise anti-tumour efficacy while prioritising patient safety. Company invests £1.4 million in a funding round that raised £68 million.
‘In December 2023, iOnctura shared positive clinical data for roginolisib, an oral allosteric modulator of PI3K? used to treat various solid and hematologic malignancies, including uveal melanoma. The funding will be utilised to expedite the development of roginolisib for treating uveal melanoma (UM), a rare eye cancer. In the Phase Ib clinical trial, roginolisib showed long-term safety and promising efficacy in UM, demonstrating sustained clinical activity over many months. Comprehensive results will be released in the upcoming months,’ it says.
Current stock price: 12.00 pence per share, closed up 0.2% on Thursday
12-month change: down 13%
Copyright 2024 Alliance News Ltd. All Rights Reserved.